View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designat...

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. The designation is based on data from the LEAP2MONO phase 3 study (clin...

 PRESS RELEASE

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation d...

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026. La Food and Drug Administration (FDA) des États-Unis a accordé la désignation de thérapie innovante au venglustat, un nouvel inhibiteur expérimental de la glucosylcéramide synthase (GCSi) administré par voie orale, pour le traitement des manifestations neurologiques de la maladie de Gaucher de type 3 (MG...

 PRESS RELEASE

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value09-Mar-2622,115€1,111.23€24,574,84310-Mar-26250€1,197.40€299,35011-Mar-2642,565€1,190.74€50,683,91212-Mar-2620,652€1,183.61€24,443,89713-Mar-2621,102€1,184.65€24,998,583 ASML’s current share buyback program was announced on 28 January 2026, and de...

Pierre FerraguÊ
  • Pierre FerraguÊ

Hybrid bonding heats up, with takeover interest emerging for Besi and ...

Reuters reported this morning that Besi has been fielding takeover interest from multiple U.S. chip-equipment makers. Besi has since then refuted these claims. Separately, ASML is reportedly entering the hybrid bonding market. Please see below for our take.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch